FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis
Once-daily roflumilast provides skin clearance and rapid itch relief with no limitation on duration of use.
Related Articles
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Hope S. Rugo, MD, Discusses Retreatment for HER2+ Breast Cancer With Trastuzumab Deruxtecan After ILD
New data shed light on the best strategies for managing patients who develop interstitial lung disease (ILD) while being treated with trastuzumab deruxtecan. City of…
American Journal of Managed Care News & Expert Insights | AJMC
The American Journal of Managed Care News section is a comprehensive resource for clinical news and expert insights. Read more at AJMC.
Clinical Perspectives Presented by:
Five-Year Outcomes With First-Line Nivolumab + Ipilimumab With Chemotherapy vs Chemotherapy in Patients With Metastatic NSCLC in CheckMate 9LA Please see US Full Prescribing Information…
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Discussing Sexuality, Mental Health With AYA Patients Amid the Hematological Treatment Journey
Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary strategy to ensure their mental and sexual well-being during…
EHA 2025 Late-Breakers Reflect Diversity of Hematology Topics, From RedirecTT-1 Combo to Frailty Scales
The late-breaking abstracts presented on the last day of the 2025 European Hematology Association (EHA) Congress show “what a vibrant clinical specialty we’re in,” according…
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation…
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.
Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years
Enrollment in Medicare coverage without out-of-pocket protections was associated with a higher likelihood of reporting cost and access barriers to care.